- Home
- ACON vs XRTX Comparison
ACON vs XRTX Comparison
Compare ACON & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACON | XRTX |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | Canada |
| Employees | 6 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 4.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ACON | XRTX |
|---|---|---|
| Price | $3.37 | $2.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 133.1K | ★ 1.8M |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $87.22 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.34 | $0.35 |
| 52 Week High | $12.03 | $3.60 |
Technical Indicators
Market Signals| Indicator | ACON | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 69.88 |
| Support Level | $3.00 | $0.52 |
| Resistance Level | $3.56 | $3.00 |
| Average True Range (ATR) | 0.29 | 0.33 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 39.18 | 55.35 |
Price Performance
Historical ComparisonAbout ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.